SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 34th Annual J.P. Morgan Healthcare Conference.
Presentation details are as follows:
Date: Wednesday, January 13, 2016
Time: 11:30 am PT
Location: Elizabethan Room B, Westin St. Francis Hotel, San Francisco
Live webcast: http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20196
The webcast and replay of the presentation will also be accessible under the “Investors/Events” section of the website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
[email protected]
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
[email protected]
[email protected]
212-845-4271
